ARCHIMMUNE Trademark

Trademark Overview

On Monday, February 21, 2022, a trademark application was filed for ARCHIMMUNE with the United States Patent and Trademark Office. The USPTO has given the ARCHIMMUNE trademark a serial number of 97276905. The federal status of this trademark filing is FOURTH EXTENSION - GRANTED as of Monday, February 24, 2025. This trademark is owned by Archimmune Therapeutics Inc.. The ARCHIMMUNE trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

Consulting services in the field of biotechnology; Consulting services in the field of pharmaceutical research and development; Research and development in the pharmaceutical and biotechnology fields; Research and development of pharmaceuticals for the treatment of age-related diseases and cancer; Research, development, engineering and testing services in the fields of immunopharmaceuticals and vaccines; Biochemical research and development; Consulting services in the field of pharmacogenetics; Pharmaceutical research and development; Scientific research and development; Vaccine research and development
archimmune

General Information

Serial Number97276905
Word MarkARCHIMMUNE
Filing DateMonday, February 21, 2022
Status733 - FOURTH EXTENSION - GRANTED
Status DateMonday, February 24, 2025
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, January 10, 2023

Trademark Statements

Goods and ServicesConsulting services in the field of biotechnology; Consulting services in the field of pharmaceutical research and development; Research and development in the pharmaceutical and biotechnology fields; Research and development of pharmaceuticals for the treatment of age-related diseases and cancer; Research, development, engineering and testing services in the fields of immunopharmaceuticals and vaccines; Biochemical research and development; Consulting services in the field of pharmacogenetics; Pharmaceutical research and development; Scientific research and development; Vaccine research and development

Classification Information

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateThursday, February 24, 2022
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameArchimmune Therapeutics Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressLexington, MA 02421
Party NameArchimmune Therapeutics Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressLexington, MA 02421

Trademark Events

Event DateEvent Description
Thursday, February 24, 2022NEW APPLICATION ENTERED
Thursday, February 24, 2022NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Monday, December 5, 2022ASSIGNED TO EXAMINER
Monday, December 5, 2022APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, December 21, 2022NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, January 10, 2023PUBLISHED FOR OPPOSITION
Tuesday, January 10, 2023OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, March 7, 2023NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Thursday, September 7, 2023SOU EXTENSION 1 FILED
Monday, October 9, 2023ABANDONMENT - NO USE STATEMENT FILED
Tuesday, October 10, 2023TEAS PETITION TO REVIVE RECEIVED
Tuesday, October 10, 2023PETITION TO REVIVE-GRANTED
Tuesday, October 10, 2023NOTICE OF REVIVAL - E-MAILED
Tuesday, October 10, 2023SOU EXTENSION RECEIVED WITH TEAS PETITION
Tuesday, October 10, 2023ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Wednesday, October 11, 2023NOTICE OF REVIVAL - E-MAILED
Monday, October 23, 2023CASE ASSIGNED TO INTENT TO USE PARALEGAL
Thursday, October 26, 2023SOU EXTENSION 1 GRANTED
Friday, October 27, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, February 5, 2024SOU TEAS EXTENSION RECEIVED
Monday, February 5, 2024SOU EXTENSION 2 FILED
Monday, February 5, 2024SOU EXTENSION 2 GRANTED
Wednesday, February 7, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, August 27, 2024SOU TEAS EXTENSION RECEIVED
Tuesday, August 27, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, August 27, 2024SOU EXTENSION 3 FILED
Monday, February 24, 2025SOU TEAS EXTENSION RECEIVED
Monday, February 24, 2025SOU EXTENSION 4 FILED
Tuesday, February 25, 2025SOU EXTENSION 4 GRANTED
Tuesday, February 25, 2025NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, August 27, 2024SOU EXTENSION 3 GRANTED

Related Keywords

archimmune research development services pharmaceutical consulting field fields biotechnology biochemical vaccines